OAKLAND, Calif. — After months of method development and validation with SCIEX Corporation, CW Analytical (CWAL), an ISO 17025 accredited Cannabis testing laboratory, today announced they will be reporting up to 55 toxic chemical residues at parts-per-billion levels using triple quadrupole mass spectrometry technology.
With this enhanced capability, CWAL will empower its clients to achieve regulatory compliance prior to the full implementation of the Medical Cannabis Regulation and Safety Act (MCRSA) and Adult Use of Marijuana Act (AUMA) in 2018. In addition, this technology will give those that test with CW Analytical the added confidence that they are providing the safest possible medicine to their patients. “This method allows us to detect these harmful compounds with unprecedented certainty and sensitivity,” said David Egerton, Vice President of Technical Operations at CW Analytical. “As LC-MS/MS technology is a highly selective technique, previous instrument-based limitations regarding false positives can be considered a thing of the past.”
While the use of pesticides in Cannabis cultivation is concerning and widespread, CW Analytical is committed to assisting those who are currently using these chemical compounds transition to organic methods. CWAL has also developed methods to aid concentrate and infused product producers in determining the cleanliness and safety of trim or flower prior to purchase using micro-extraction techniques.
Despite recent sensationalist reporting, Cannabis remains a safe alternative medicine that has been used successfully for thousands of years. The CWAL team is heartened by the dedication of the California Cannabis industry to evolve and produce safer, cleaner Cannabis than ever before, and serve as an example to producers of other agricultural products.
2017 is an important transitionary time for the industry as the state of CA begins to release testing and other industry regulations. CWAL urges cultivators and producers to work with their preferred ISO accredited laboratory to make this transition smooth and compliance simple. “CW Analytical remains committed to the health of Cannabis consumers and the future success of California Cannabis businesses,” said Robert Martin, Ph.D., CW Analytical Co-founder and COO. “Ultimately, this will ensure California’s leadership role in the emerging global Cannabis industry.”
About CW Analytical
Founded in 2009 by a chemist and a microbiologist, CW Analytical’s team of scientists and industry experts has been providing patients, cultivators, producers and dispensaries in California with important information about the safety, quality, and potency of their medical Cannabis products long before any state mandate.
The company’s commitment to continuous innovation and technical development has led to strategic partnerships with companies like SCIEX and the achievement of ISO 17025 accreditation in August of 2016.
CW Analytical’s continued success is due to its ability to provide clients with accurate data at an affordable price coupled with quick turnaround times and unrivaled customer service. The company’s mission is to enable clients to better serve their patients and compete in the medical Cannabis marketplace with the safest, cleanest, and most consistent medicine in California.